Phase I Study of PM534 Administered to Patients with Advanced Solid Tumors

2024-513056-15-00 Protocol PM534-A-001-22 Phase I and Phase II (Integrated) - First administration to humans Ongoing, recruiting

Start 1 Dec 2022 · Status Ongoing, recruiting · 1 EU/EEA countries · 3 sites · Protocol PM534-A-001-22

Overview

Sponsor-declared trial summary

Phase Phase I and Phase II (Integrated) - First administration to humans
Status Ongoing, recruiting
Participants planned 145
Countries 1
Sites 3

Advanced Solid Tumors

Key facts

Sponsor
Pharma Mar S.A.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
1 Dec 2022 → ongoing
Decision date (initial)
2024-04-30
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2024-513056-15-00
EudraCT number
2022-002032-31
ClinicalTrials.gov
NCT05835609

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Advanced Solid Tumors

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Pharma Mar S.A.

Sponsor organisation
Pharma Mar S.A.
Address
Avenida De Los Reyes 1, Poligono Industrial La Mina Poligono Industrial La Mina
City
Colmenar Viejo
Postcode
28770
Country
Spain

Scientific contact point

Organisation
Pharma Mar S.A.
Contact name
Clinical Development Oncology Unit

Public contact point

Organisation
Pharma Mar S.A.
Contact name
Clinical Development Oncology Unit

Locations

1 EU/EEA country · 3 investigational sites

By country

CountryMS statusPlanned subjectsSites
Spain Ongoing, recruiting 145 3
Rest of world 0

Investigational sites

Spain

3 sites · Ongoing, recruiting
Hospital Universitario Hm Sanchinarro
START Madrid-HM CIOCC, Calle Ona 10, 28050, Madrid
Hospital Hm Nou Delfos
START Barcelona, Avinguda De Vallcarca 151, 08023, Barcelona
Hospital Universitario Fundacion Jimenez Diaz
START Madrid-FJD, Avenida De Los Reyes Catolicos 2, 28040, Madrid

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Spain 2022-12-01 2022-12-23

Application history

5 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-04-26 Spain Acceptable
2024-04-30
2024-04-30
2 SUBSTANTIAL MODIFICATION SM-1 2024-11-15 Spain Acceptable
2025-01-27
2025-02-05
3 SUBSTANTIAL MODIFICATION SM-2 2025-03-24 Spain Acceptable
2025-05-07
2025-05-07
4 SUBSTANTIAL MODIFICATION SM-3 2025-07-21 Spain Acceptable 2025-07-24
5 SUBSTANTIAL MODIFICATION SM-5 2025-12-22 Spain Acceptable
2026-03-28
2026-04-06